Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Synerx Pharma has received approval of its abbreviated new drug application for malathion lotion, 0.5%. The product represents the first approval of a generic equivalent to Ovide.
Subscribe to our email newsletter
The abbreviated new drug application approval is the result of an extensive, multi-year development program. Efforts to commercialize the product are now being pursued by Synerx.
Ovide lotion is indicated for patients infected with pediculus humanus capitis of the scalp hair.